Shares of Insmed Incorporated (INSM) plummeted over 6% in pre-market trading on Thursday, after the biopharmaceutical company reported weaker-than-expected earnings for the third quarter of 2024 and provided a disappointing outlook.
For Q3, Insmed posted a loss of $1.27 per share, missing analysts' consensus estimate of $1.21 per share. The company's revenue of $93.4 million beat expectations of $93.3 million, driven by sales of its flagship drug Arikayce for the treatment of a rare lung disease.
However, Insmed reiterated its full-year 2024 guidance for global Arikayce revenues of $340 million to $360 million, which fell short of analysts' projections. The company also announced a new $150 million senior secured term loan tranche, raising concerns about its financial position and cash burn.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。